NCT03832569 2026-03-05
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
33 trialsNCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT04265872 2026-02-12
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
NCT05493566 2026-02-12
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
Phase EARLY_PHASE1 Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05041153 2026-01-12
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT03276832 2025-10-28
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT05488366 2025-09-22
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
University of California, Irvine
Phase EARLY_PHASE1 Active not recruiting
NCT06308913 2025-07-15
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
University of Wisconsin, Madison
Phase EARLY_PHASE1 Recruiting
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT04134325 2025-04-16
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06637306 2025-03-26
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT05733715 2025-03-03
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT02872025 2025-01-30
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
University of California, San Francisco
Phase EARLY_PHASE1 Active not recruiting
NCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT04188951 2024-12-04
HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer
Henry Ford Health System
Phase EARLY_PHASE1 Completed
NCT03514121 2024-11-22
FPA150-001
Five Prime Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT02981914 2024-04-22
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
Phase EARLY_PHASE1 Completed
NCT04541108 2024-04-18
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Recruiting
NCT02728830 2024-02-21
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Duke University
Phase EARLY_PHASE1 Completed
NCT06212388 2024-01-25
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
Xijing Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown
NCT03694834 2023-11-28
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03395847 2023-11-18
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT04777708 2023-03-24
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03099564 2023-02-06
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
Hoosier Cancer Research Network
Phase EARLY_PHASE1 Unknown
NCT02591654 2022-12-30
MPAK
Columbia University
Phase EARLY_PHASE1 Terminated
NCT03197389 2021-05-19
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Completed
NCT04220892 2020-07-31
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
Saint John's Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03574220 2020-04-07
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT03291353 2019-04-19
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
University of Pittsburgh
Phase EARLY_PHASE1 Withdrawn